Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
53,840,366
-
Share change
-
+1,535,687
-
Total reported value
-
$554,583,076
-
Put/Call ratio
-
38%
-
Price per share
-
$10.30
-
Number of holders
-
95
-
Value change
-
-$2,768,794
-
Number of buys
-
48
-
Number of sells
-
39
Institutional Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q3 2023
As of 30 Sep 2023,
AVADEL PHARMACEUTICALS - COM (AVDL) was held by
95 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,840,366 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, RTW INVESTMENTS, LP, GENDELL JEFFREY L, Polar Capital Holdings Plc, Vivo Capital, LLC, WEALTH EFFECTS LLC, COWEN AND COMPANY, LLC, Woodline Partners LP, ADAGE CAPITAL PARTNERS GP, L.L.C., and BRANDES INVESTMENT PARTNERS, LP.
This page lists
96
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.